¿Qué características de sars-cov-2 se consideran en el desarrollo de vacunas?
(What features of sars-cov2 are targeted in vaccine development?)
Primeras 5 respuestas:
-
To enhance the magnitude and quality of the adaptive response, adjuvants are included in some vaccination formulations [24] .
-
The development of a safe and effective vaccine, therefore, is vital for mass protection of those most at risk from COVID-19-induced disease.
-
Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor.
-
live attenuated virus, viral vectors, inactivated virus, subunit vaccines, recombinant DNA, and protein vaccines.
-
CoVs encodes multiple structural and non-structural proteins.
To enhance the magnitude and quality of the adaptive response, adjuvants are included in some vaccination formulations [24] .
... To enhance the magnitude and quality of the adaptive response, adjuvants are included in some vaccination formulations [24] . Different adjuvants drive different immunological signatures and, hence, are optimal for protection against different pathogens [25] . For example, adjuvants can modulate the ratio of T helper 1 (Th1) and ...
Ref: COVID‐19 vaccines: knowing the unknown [Eur J Immunol, 2020-05-21]The development of a safe and effective vaccine, therefore, is vital for mass protection of those most at risk from COVID-19-induced disease.
... if immunity is not long-lived (97) . The development of a safe and effective vaccine, therefore, is vital for mass protection of those most at risk from COVID-19-induced disease. This will reduce the number of hospitalised cases, subsequently relieving the burden on healthcare systems and will allow for relaxation of physical distancing ...
Ref: The early landscape of COVID‐19 vaccine development in the UK and rest of the world [Immunology, 2020-05-27]Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor.
... door for investigators to design vaccine concepts and approaches for the COVID-19 epidemic in China. Both SARS-CoV and SARS-CoV-2 exhibit a high degree of genetic similarity and bind to the same host cell ACE2 receptor. Based on previous experience with SARS-CoV vaccines, it is expected that all COVID-19 vaccines will ...
Ref: The SARS-CoV-2 Vaccine Pipeline: an Overview [Curr Trop Med Rep, 2020-03-03]live attenuated virus, viral vectors, inactivated virus, subunit vaccines, recombinant DNA, and protein vaccines.
... to prevent SARS-CoV-2 infection (14) . There are different vaccine development platforms against SARS-CoV-2, including live attenuated virus, viral vectors, inactivated virus, subunit vaccines, recombinant DNA, and protein vaccines. Several studies are in progress, but requires months to years to develop the vaccines for ...
Ref: A review on Promising vaccine development progress for COVID-19 disease [Vacunas, 2020-06-13]CoVs encodes multiple structural and non-structural proteins.
... SARS-CoV-2 infections and affected countries, efforts for developing an effective SARS-CoV-2 vaccine are urgently required. CoVs encodes multiple structural and non-structural proteins. The structural proteins include the spike (S) protein, the envelope (E) protein, the membrane (M) ...
Ref: Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A Systematic Review [Int Immunopharmacol, 2020-06-28]Vaccines for acute viral infections are developed such that they can recapitulate immune reactions towards natural infections [112] .
... Vaccines for acute viral infections are developed such that they can recapitulate immune reactions towards natural infections [112] . Basic knowledge is now absent for COVID-19, including whether equilibrium and the type of cells that respond to the virus differ corresponding to the course and its severity. This understanding ...
Ref: Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine [Int Immunopharmacol, 2020-08-24]Immunoinformatic and molecular modelling are time-efficient methods that are generally used to accelerate the discovery and design of the candidate peptides for vaccine development.
... a few repurposed drugs. The urgency of the situation requires the development of SARS-CoV-2-based vaccines. Immunoinformatic and molecular modelling are time-efficient methods that are generally used to accelerate the discovery and design of the candidate peptides for vaccine development. In recent years, the use of multiepitope vaccines has proved to be a promising immunization ...
Ref: A Putative Prophylactic Solution for COVID-19: Development of Novel Multiepitope Vaccine Candidate against SARS-COV-2 by Comprehensive Immunoinformatic and Molecular Modelling Approach. [Biology, 2020-09-18]The spike glycoprotein (S protein) is now a key target for vaccine development, therapeutic antibody generation, and the clinical diagnosis of COVID-19.
... Finding the most suitable target site for SARS-CoV-2 vaccine development is extremely important. The spike glycoprotein (S protein) is now a key target for vaccine development, therapeutic antibody generation, and the clinical diagnosis of COVID-19. ...
Ref: An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development [Med Sci Monit, 2020-05-05]Many seek to induce neutralizing antibodies (nAbs) to the spike (S) protein on the surface of the virus,
... Landscape Currently, more than 70 vaccine candidates to SARS-CoV-2 are at some stage of development. Many seek to induce neutralizing antibodies (nAbs) to the spike (S) protein on the surface of the virus, given the association of nAbs with protection for many successful viral vaccines (Figure 1 ). ...
Ref: Rational Vaccine Design in the Time of COVID-19 [Cell Host Microbe, 2020-05-13]An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors.
... a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or ...
Ref: Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses [Int Immunopharmacol, 2020]Vaccine candidates against SARS-CoV-2 are mainly based upon the viral spike protein due to its vital role in viral infectivity,
... up the establishment of a variety of vaccine platforms. Accordingly, numerous vaccines are under development. Vaccine candidates against SARS-CoV-2 are mainly based upon the viral spike protein due to its vital role in viral infectivity, and most of these candidates have recently moved into clinical trials. Before the efficacy of ...
Ref: Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines [Biomed J, 2020]pharmaceutical formulation science plays a critical role throughout the development, manufacturing, distribution, and vaccination phases.
... In the race for a safe and effective vaccine against coronavirus disease (COVID)-19, pharmaceutical formulation science plays a critical role throughout the development, manufacturing, distribution, and vaccination phases. The proper choice of the type of vaccine, carrier or vector, adjuvant, excipients, dosage form, and route ...
Ref: The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation [AAPS PharmSciTech, 2020]Several subunit vaccines, peptides, nucleic acids, plant-derived, recombinant vaccines are under pipeline.
... SARS-CoV-2 vaccine started based on the full-length genome analysis of severe acute respiratory syndrome coronavirus. Several subunit vaccines, peptides, nucleic acids, plant-derived, recombinant vaccines are under pipeline. This article concludes and highlights ongoing advances in drug repurposing, therapeutics and vaccines to counter ...
Ref: An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario [J. basic clin. physiol. pharmacol, 2020]To mitigate the public health, economic and societal impacts of the virus, a vaccine is urgently needed.
... (SARS-CoV-2) emerged in late 2019 in China and caused a coronavirus disease 2019 (COVID-19) pandemic. To mitigate the public health, economic and societal impacts of the virus, a vaccine is urgently needed. The development of SARS-CoV-2 vaccines was initiated in early January 2020 when the sequence of ...
Ref: SARS-CoV-2 vaccines in development. [Nature, 2020-09-23]Factors from essential features of safety, efficacy, manufacturing, and distributions to administration approaches are taken into consideration based on advances in materials science and engineering technologies.
... pushed into clinical trials simultaneously, and manufacturing capability must be scaled up in early stages. Factors from essential features of safety, efficacy, manufacturing, and distributions to administration approaches are taken into consideration based on advances in materials science and engineering technologies. In this review, we present recent advances in vaccine development by focusing on vaccine discovery, ...
Ref: Engineering Antiviral Vaccines [ACS nano, 2020]The CoV spike receptor-binding domain (RBD) is an attractive vaccine target but is undermined by limited immunogenicity.
... to control the ongoing pandemic COVID-19 and previously emerging MERS/SARS caused by coronavirus (CoV) infections. The CoV spike receptor-binding domain (RBD) is an attractive vaccine target but is undermined by limited immunogenicity. We describe a dimeric form of MERS-CoV RBD that overcomes this limitation. The RBD-dimer significantly ...
Ref: A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS [Cell, 2020]The roles of S protein in receptor binding and membrane fusion makes it a prominent target for vaccine development.
... cellsis initiated by the binding of the viral spike protein (S) to its cellular receptor. The roles of S protein in receptor binding and membrane fusion makes it a prominent target for vaccine development. SARS-CoV-2 genome sequence analysis has shown that this virus belongs to the beta-coronavirus genus, which ...
Ref: Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. [Human vaccines & immunotherapeutics, 2020-08-12]antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection.
... Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection. ...
Ref: Approaches and Challenges in SARS-CoV-2 Vaccine Development [Human vaccines & immunotherapeutics, 2020]both these viruses bind to same host cell receptor ACE-2.
... suggested that genomic sequence of SARS-CoV-2 is almost 80% similar to that of SARS-CoV, further both these viruses bind to same host cell receptor ACE-2. Hence it is expected that, previously available literature data about coronavirus vaccine designing may play ...
Ref: Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges [Diabetes Metab Syndr, 2020]Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2),
... worldwide, thus calling for development of vaccines against SARS-CoV-2 and other emerging and reemerging coronaviruses. Since SARS-CoV-2 and SARS-CoV have high similarity of their genomic sequences and share the same cellular receptor (ACE2), it is essential to learn the lessons and experiences from the development of SARS-CoV vaccines ...
Ref: cord_uid a9i6j9f9 From SARS-CoV to SARS-CoV-2: safety and broad-... a9i6j9f9 From SARS-CoV to SARS-CoV-2: safety and broad-... Name: title, dtype: object [Diabetes Metab Syndr, cord_uid a9i6j9f9 2020 a9i6j9f9 2020 Name: publish_time, dtype: object]The spike protein is also a critical target for vaccine development.
... monoclonal antibodies. Medications are being developed to target the spike, membrane, nucleocapsid or envelope proteins. The spike protein is also a critical target for vaccine development. Immunoinformatic approaches are being used for the identification of B cell and cytotoxic T lymphocyte ...
Ref: Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development [Diabetes Metab Syndr, 2020]Future vaccines must ensure the scalability, an adequate price for sustainable investment, and equitable distribution of life-saving vaccines.
... vaccine, multiple products are needed to meet the enormous global demand. Speeding up the development of new vaccines against SARS-CoV-2 is important, but ensuring safety and efficacy in clinical trials. Future vaccines must ensure the scalability, an adequate price for sustainable investment, and equitable distribution of life-saving vaccines. ...
Ref: Vaccine development in the SARS-CoV-2 pandemic: a balancing act on accuracy and speed [Int J Public Health, 2020-10-13]nucleic acids, protein subunit, replicating viral vector, non-replicating viral vector, and inactivated virus approaches.
... The wide ranges of technologies that are being developed for SARS-CoV-2 include nucleic acids, protein subunit, replicating viral vector, non-replicating viral vector, and inactivated virus approaches. Newer approaches based on nucleic acids such as DNA or mRNA can facilitate potentially rapid production, as they ...
Ref: Coronavirus Vaccine: Light at the End of the Tunnel [Indian Pediatr, 2020-04-15]While multiple vaccine platforms against SARS-CoV-2 focus on the S protein, questions remain regarding the key elements of a protective immune response.
While multiple vaccine platforms against SARS-CoV-2 focus on the S protein, questions remain regarding the key elements of a protective immune response.
Ref: The Challenges of Vaccine Development against a New Virus during a Pandemic [Cell Host Microbe, 2020-05-13]development of different types of vaccines including DNA, mRNA, viral vector, inactivated, subunit and vaccine-like particles is in process.
... approved so far against this virus. Nevertheless, several potential vaccine targets have been reported, and development of different types of vaccines including DNA, mRNA, viral vector, inactivated, subunit and vaccine-like particles is in process. It is concluded that a suitable candidate delivered through an advanced drug delivery approach would ...
Ref: COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. [Pharmaceutics, 2020-10-03]target the receptor binding domain that engages human angiotensin-converting enzyme-2 (ACE2).
... from SARS-CoV-2. Immunization of mice with VSV-eGFP-SARS-CoV-2 elicits high antibody titers that neutralize SARS-CoV-2 and target the receptor binding domain that engages human angiotensin-converting enzyme-2 (ACE2). Upon challenge with a human isolate of SARS-CoV-2, mice that expressed human ACE2 and were ...
Ref: Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice [Cell Host Microbe, 2020]A vaccine must stimulate effective antibody and T cell responses in vivo to induce long-term protection.
... 2 (SARS-CoV-2), a novel coronavirus, is essential for stopping the current coronavirus disease (COVID-19) pandemic. A vaccine must stimulate effective antibody and T cell responses in vivo to induce long-term protection. Scientific researchers have been developing vaccine candidates for the severe acute respiratory syndrome (SARS) and ...
Ref: SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies [Cell Host Microbe, 2020]Vaccine candidates target spike (S) and nucleocapsid proteins, including subunit and recombinant vector vaccines, as well as DNA vaccines [7] .
... SARS-CoV-2"s complete sequences have an impact on developing vaccines and antiviral agents [6] . Vaccine candidates target spike (S) and nucleocapsid proteins, including subunit and recombinant vector vaccines, as well as DNA vaccines [7] . Lucchese [18] proposed unique pentapeptides of SARS-CoV-2 that are considered as preventive measures against novel coronavirus ...
Ref: Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2 [Vaccines (Basel), 2020-06-10]A safe and effective vaccine against SARS-CoV2 virus might be available by the end of 2020 or beginning of 2021.
... Vaccination is one of the most cost-effective strategy for prevention of diseases. A safe and effective vaccine against SARS-CoV2 virus might be available by the end of 2020 or beginning of 2021. Even if a safe and effective vaccine is available, it may not be possible to obtain the required ...
Ref: Vaccine Against Covid-19 Disease – Present Status of Development [Indian J Pediatr, 2020-09-03]Solubility and physicochemical property assessments of the primary sequence of vaccine candidates are essential for determining the state, stability, and accessibility of a vaccine.
... 2.0 (http://www.molbiotools.com/WebDSV/) was used for pursuing the in-silico cloning of peptidebased vaccine component against SARS-CoV-2. Solubility and physicochemical property assessments of the primary sequence of vaccine candidates are essential for determining the state, stability, and accessibility of a vaccine. The solubility of the construct vaccine was predicted against the average solubility of E. coli ...
Ref: A SARS-CoV-2 vaccine candidate: In silico cloning and validation [Inform Med Unlocked, 2020-07-15]Therapeutic and prophylactic strategies to deal with existing and potentially upcoming coronavirus infections are under development.
... binding, causing further morbidity and mortality. 74, 75 THERAPEUTIC DEVELOPMENT AND VACCINE DEVELOPMENT Therapeutic Development. Therapeutic and prophylactic strategies to deal with existing and potentially upcoming coronavirus infections are under development. The symptomatic treatment approach is presently followed in the absence of an exclusive antiviral treatment ...
Ref: Nanotechnology for COVID-19: Therapeutics and Vaccine Research [ACS Nano, 2020-06-22]A promising approach for vaccine development is to generate, through codon pair deoptimization, an attenuated virus.
... pandemic is rapidly progressing, the need for the development of an effective vaccine is critical. A promising approach for vaccine development is to generate, through codon pair deoptimization, an attenuated virus. This approach carries the advantage that it only requires limited knowledge specific to the virus ...
Ref: Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design [Sci Rep, 2020]coronavirus spike protein is the major antigen for the vaccine design as it can induce neutralizing antibodies and protective immunity
... SARS-CoV-2, that may also cover other pathogenic coronaviruses as a potentially universal vaccine In general, coronavirus spike protein is the major antigen for the vaccine design as it can induce neutralizing antibodies and protective immunity By considering the high genetic similarity between SARS-CoV and SARS-CoV-2, here, protective immunity against SARS-CoV ...
Ref: Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development [Journal of Immunology Research, 2020]Both SARS-CoV and SARS-CoV-2 has a high degree of genetic similarity and bind to the same host cell ACE2 receptor.
... have opened the door for the scientist to design a new vaccine for the COVID-19. Both SARS-CoV and SARS-CoV-2 has a high degree of genetic similarity and bind to the same host cell ACE2 receptor. By using different vaccine development platforms including whole virus vaccines, recombinant protein subunit vaccines, and ...
Ref: A review on Promising vaccine development progress for COVID-19 disease [Vacunas (Madrid), 2020]A rapid SARS-CoV2 vaccine development approach involves the integration of computational and structural-based immunogen design strategies,
... vaccine trial developed by the VRC in collaboration with Moderna had begun (NIH, 2020) . A rapid SARS-CoV2 vaccine development approach involves the integration of computational and structural-based immunogen design strategies, production of immunogens as inactivated virus, DNA, mRNA, vectored or protein subunits, and immunogenic profiling ...
Ref: Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19 [Cell, 2020-05-27]There are currently about 60 vaccine candidates in the preclinical development stage, including RNA, DNA, protein subunit, vector, and inactivated vaccines.
... commenced. The WHO convened experts to develop a global research and development strategy for COVID-19, including vaccine development [2] . There are currently about 60 vaccine candidates in the preclinical development stage, including RNA, DNA, protein subunit, vector, and inactivated vaccines. Several are currently in phase I clinical trials [3] . ...
Ref: Enabling Emergency Mass Vaccination: Innovations in Manufacturing and Administration During a Pandemic [Vaccine, 2020-04-20]S protein was found to elicit neutralising antibody and is a major target antigen for vaccine development.
... and entry into the cell (Figure 1 ). In SARS-CoV, of all the structural proteins, S protein was found to elicit neutralising antibody and is a major target antigen for vaccine development. [23] [ 24] There have been difficulties in the development of coronavirus vaccines historically. Coronavirus ...
Ref: Vaccines for COVID-19: the current state of play [Paediatr Respir Rev, 2020-06-18]MSCs may reduce the pathological changes that occur in the lungs and inhibit the cell-mediated inflammatory response.
... various diseases. MSCs are being investigated in a clinical trial for COVID-19, which focuses on the safety and efficiency of MSC therapy for pneumonia patients infected with SARS-CoV-2 [37] . MSCs may reduce the pathological changes that occur in the lungs and inhibit the cell-mediated inflammatory response. ...
Ref: COVID-19: An Update Regarding the Quest for Finding an Effective Cure [Cureus, 2020-07-05]There are more than 164 candidate vaccines which are in the process of development and among them 24 vaccines are in advanced stages of development.
... expected that there shall be simultaneous marketing of several vaccines by the beginning of 2021. There are more than 164 candidate vaccines which are in the process of development and among them 24 vaccines are in advanced stages of development. This review aims at highlighting the present stages of development of vaccines and discussing the ...
Ref: Vaccine Against Covid-19 Disease - Present Status of Development [Indian J Pediatr, 2020]To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity.
... coronavirus disease 2019 (COVID‐19) caused by the novel virus SARS‐CoV‐2 has claimed many lives worldwide. To combat the pandemic, multiple types of vaccines are under development with unprecedented rapidity. Theoretically, the future vaccination against COVID‐19 may fall into long‐term costly guerrilla warfare between SARS‐CoV‐2 ...
Ref: Potential for elimination of SAR‐CoV‐2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination [J Med Virol, 2020-06-11]We focus on vaccine development in the UK and vaccines that have entered clinical trials around the world.
... unprecedented pace across the world. Here we review the different platforms employed to develop vaccines, the standard timelines of development and how they can be condensed in a pandemic situation. We focus on vaccine development in the UK and vaccines that have entered clinical trials around the world. ...
Ref: The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world [Immunology, 2020]Using this well known, safe vaccine backbone, we demonstrate here induction of functional immune responses in both arms of adaptive immunity with the desired immune bias.
... search for such a concept, we have analysed a measles virus-based vaccine candidate targeting SARS-CoV-2. Using this well known, safe vaccine backbone, we demonstrate here induction of functional immune responses in both arms of adaptive immunity with the desired immune bias. Therefore, occurrence of immunopathologies such as antibody-dependent enhancement or enhanced respiratory disease is rather unlikely. ...
Ref: A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 Vaccine [bioRxiv, 2020-07-11]Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs.
... success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the ...
Ref: Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks [Health Secur, 2020]The current response to the COVID-19 pandemic involves aggressive implementation of containment, suppression, and mitigation strategies.
... The current response to the COVID-19 pandemic involves aggressive implementation of containment, suppression, and mitigation strategies. Such an approach encompasses the enforcement of a variety and combination of public health measures including hand hygiene and respiratory etiquette, disinfection, case identification, isolation of sick people, tracing and ...
Ref: When a COVID-19 vaccine is ready, will we all be ready for it? [Int J Public Health, 2020-06-11]The different vaccine platforms being tested are Bacillus Calmette-Guérin (BCG) vaccines, DNA and RNA-based vaccines,
... light on the 16 current approved clinical trials worldwide in search for a COVID-19 vaccine. The different vaccine platforms being tested are Bacillus Calmette-Guérin (BCG) vaccines, DNA and RNA-based vaccines, inactivated vaccines, protein subunits, and viral vectors. By thoroughly analyzing different trials and platforms, we ...
Ref: Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand? [Viruses, 2020]targeting the deoxyribonucleic acid (DNA), messenger ribonucleic acid (mRNA), and viral minigenes
... we have summarized data on cell receptor interactions and data on prospects of new vaccines targeting the deoxyribonucleic acid (DNA), messenger ribonucleic acid (mRNA), and viral minigenes We have tabulated the available data on various clinical trials testing various aspects of COVID-19 ...
Ref: The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts [Cureus, 2020]The coronavirus 3CL hydrolase (Mpro) enzyme is essential for proteolytic maturation of the virus.
... present study provides the first multiepitope vaccine construct using the 3CL hydrolase protein of SARS-CoV-2. The coronavirus 3CL hydrolase (Mpro) enzyme is essential for proteolytic maturation of the virus. This study was based on immunoinformatics and structural vaccinology strategies. The design of the multiepitope ...
Ref: cord_uid ggbtwmiv 3CL hydrolase-based multiepitope peptide vacci... ggbtwmiv 3CL hydrolase-based multiepitope peptide vacci... Name: title, dtype: object [Cureus, cord_uid ggbtwmiv 2020 ggbtwmiv 2020 Name: publish_time, dtype: object]Progresses on the development of potential therapeutics and vaccines that are under the preclinical studies and clinical trials have been highlighted.
... revisited the druggable targets that may hold promise in the development of the anti-SARS-CoV-2 agent. Progresses on the development of potential therapeutics and vaccines that are under the preclinical studies and clinical trials have been highlighted. We anticipate that this review will provide valuable information that would help to accelerate the ...
Ref: Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review [Drug dev. res, 2020]Targeted therapies including the use of antibodies to prevent virus entry, nucleotide analogues to prevent viral replication, and inhibitors of proteases to prevent virion formation,
... MERS-CoV to develop therapies that specifically target SARS-CoV-2 and to develop vaccines to prevent COVID-19. Targeted therapies including the use of antibodies to prevent virus entry, nucleotide analogues to prevent viral replication, and inhibitors of proteases to prevent virion formation, among others, are being tested for their clinical efficacy. Likewise, complete sequencing of the SARS-CoV-2 ...
Ref: Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries [Cardiovasc Pathol, 2020]Developing these vaccines is fundamental to public health.
... need for the rapid development of a vaccine against SARS-CoV-2 for effective and sustainable control. Developing these vaccines is fundamental to public health. This urgent need is supported by the scientific explosion in structural and genomic biology that ...
Ref: Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development [Immunol. res, 2020]The structural proteins of SARS-CoV-2 involved in its survival and pathogenicity were used to predict antigenic epitopes.
... a preventive measure, we have computationally designed a multi-epitopic subunit vaccine using immuno-informatic approaches. RESULTS: The structural proteins of SARS-CoV-2 involved in its survival and pathogenicity were used to predict antigenic epitopes. The antigenic epitopes were capable of eliciting a strong humoral as well as cell-mediated immune ...
Ref: Exploring the SARS-CoV-2 structural proteins for multi-epitope vaccine development: an in-silico approach [Expert Rev Vaccines, 2020]Angiotensin-Converting Enzyme 2 (ACE2) and uses it as an entry receptor to invade target cells 39 [1] .
... Angiotensin-Converting Enzyme 2 (ACE2) and uses it as an entry receptor to invade target cells 39 [1] . Therefore, the spike protein of SARS-CoV is anticipated to be an important component of The main information that would help us to choose desirable epitopes is to figure out which ...
Ref: Development of a novel platform of virus-like particle (VLP) based vaccine against coronavirus 2019 (SARS-CoV-2) by exposing of epitopes: an immunoinformatics approach [New Microbes New Infect, 2020-10-14]The native S proteins exist as a trimeric form on the surface of virus.
... The native S proteins exist as a trimeric form on the surface of virus. However, when its ectodomain or S1 is expressed as a recombinant protein in eukaryotic systems, the protein exists predominantly in a monomeric form (Li et al., 2013; Kim et al., ...
Ref: Challenges and prospects of COVID‐19 vaccine development based on the progress made in SARS and MERS vaccine development [Transbound Emerg Dis, 2020-08-20]a major challenge during rapid development is to avoid safety issues both by thoughtful vaccine design and by thorough evaluation in a timely manner.
... one hundred vaccine candidates in development and at least six having reached clinical trials. However, a major challenge during rapid development is to avoid safety issues both by thoughtful vaccine design and by thorough evaluation in a timely manner. A syndrome of "disease enhancement" has been reported in the past for a few viral ...
Ref: Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines [Vaccine, 2020]the presented respiratory vaccine candidate is highly attenuated in primates per se, safe and lacking pre-existing immunity in human,
... and this expression did not significantly impact the in vitro growth characteristics of the recombinant Taken together, the presented respiratory vaccine candidate is highly attenuated in primates per se, safe and lacking pre-existing immunity in human, and carries the potential for accelerated vaccine development against CoVID-19 for clinical studies ...
Ref: A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2 [Vaccines, 2020]Immunization has helped save millions of lives from preventable and fatal diseases.
... aspect of dealing with the resilient pathogens in the past has been the coveted vaccine. Immunization has helped save millions of lives from preventable and fatal diseases. In this review, we will briefly discuss the highly sought vaccine for COVID-19, the dynamics, ...
Ref: COVID-19: A Review of Emerging Preventative Vaccines and Treatment Strategies [Cureus, 2020-05-20]Designed construct comprises of epitopes capable of inducing T cell, B cell (Linear and discontinuous) and Interferon γ.
... S2 subunit of the SARS-CoV2 S glycoprotein has been designed using open source, immunoinformatics tools. Designed construct comprises of epitopes capable of inducing T cell, B cell (Linear and discontinuous) and Interferon γ. physiologically, vaccine construct is predicted to be thermostable, antigenic, immunogenic, non allergen and non toxic ...
Ref: Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach. [Journal of biomolecular structure & dynamics, 2020-07-03]Promising targets include NSPs, which are involved in transcription and replication of the virus, as the key enzymes in the viral lifecycle.
... lifecycle steps provide potential targets for vaccines and therapeutics to prevent and treat SARS-CoV-2 infection. Promising targets include NSPs, which are involved in transcription and replication of the virus, as the key enzymes in the viral lifecycle. Additional targets include viral entry and immune regulation pathways. For example, the S protein plays ...
Ref: COVID-19: Progress in diagnostics, therapy and vaccination [Theranostics, 2020-06-19]it is imperative that a safe and effective vaccine be developed promptly for global availability.
... With the SARS-CoV-2 pandemic creating such a wide-reaching health crisis, it is imperative that a safe and effective vaccine be developed promptly for global availability. As such, there are several vaccine development projects currently underway aiming to meet this critical demand. However, COVID vaccine development ...
Ref: SARS-CoV-2 Vaccine [Glob Reprod Health, 2020-09-02]We also describe host immune responses to highly pathogenic human coronaviruses in terms of innate and adaptive immunities.
... needs to be understood for the development of an efficient and safe vaccine. Here, we review the current understanding of vaccine targets and the status of vaccine development for COVID-19. We also describe host immune responses to highly pathogenic human coronaviruses in terms of innate and adaptive immunities. ...
Ref: Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses. [Journal of microbiology and biotechnology, 2020-06-16]we review pre-clinical progress and ongoing human clinical trials of COVID-19 vaccine candidates.
... prophylactic interventions for SARS-CoV-2 with a focus on the challenges existing for vaccine development, and we review pre-clinical progress and ongoing human clinical trials of COVID-19 vaccine candidates. Although COVID-19 vaccine development is currently accelerated via so-called fast-track programs, vaccines may not be ...
Ref: The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies [Front Immunol, 2020]a The Spike protein of SARS-CoV-2 is known to be critical for virus' entry into the cells.
... and production of an RBD-based vaccine and inspecting its protective effects in in vivo models. a The Spike protein of SARS-CoV-2 is known to be critical for virus" entry into the cells. Rational design of the vaccine involves the insertion of a GP67 signal peptide upstream to ...
Ref: Is smaller better? Vaccine targeting recombinant receptor-binding domain might hold the key for mass production of effective prophylactics to fight the COVID-19 pandemic [Signal Transduct Target Ther, 2020-10-06]The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein.
... The best therapeutic strategy to find an effective vaccine against SARS-CoV-2 is to explore the target structural protein. In the present study, a novel multi-epitope vaccine is designed using in silico tools that potentially trigger both CD4 and CD8 T-cell immune responses against the novel Coronavirus. The vaccine ...
Ref: cord_uid 8oxi1z0t Design of multi-epitope vaccine candidate agai... 8oxi1z0t Design of multi-epitope vaccine candidate agai... Name: title, dtype: object [Signal Transduct Target Ther, cord_uid 8oxi1z0t 2020 8oxi1z0t 2020 Name: publish_time, dtype: object]SARS-CoV-2 depends for entry on angiotensin-converting enzyme 2 (ACE2)
... Finally, the route of administration could also affect the quality of the induced immune response. SARS-CoV-2 depends for entry on angiotensin-converting enzyme 2 (ACE2) which is expressed mainly on the surface of epithelial cells in the respiratory tract and ...
Ref: Current status of COVID‐19 (pre)clinical vaccine development [Angew Chem Int Ed Engl, 2020-07-14]Designed construct comprises of epitopes capable of inducing T cell, B cell (Linear and discontinuous) and Interferon γ.
... S2 subunit of the SARS-CoV2 S glycoprotein has been designed using open source, immunoinformatics tools. Designed construct comprises of epitopes capable of inducing T cell, B cell (Linear and discontinuous) and Interferon γ. physiologically, vaccine construct is predicted to be thermostable, antigenic, immunogenic, non allergen and non toxic ...
Ref: Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach [J Biomol Struct Dyn, 2020]They are protein-based vaccines, viral vector vaccines, DNA or RNA vaccines and inactivated or attenuated viral vaccines.
... ninety vaccines are currently being developed against Sars-Cov2 by universities and companies around the world. They are protein-based vaccines, viral vector vaccines, DNA or RNA vaccines and inactivated or attenuated viral vaccines. The development of a vaccine starts from the identification and characterization of the microorganism that ...
Ref: [Vaccines: from the identification of the microorganism to marketing. How long does it take?] [Igiene e sanita pubblica, 2020]In de novo drug discovery, it is fundamental to understand the molecular entities and specific pathways driving the virus replication during infection.
... for SARS-CoV-2 outbreak, it is vital to find new targets for novel therapeutic anti-SARS-CoV-2 approach. In de novo drug discovery, it is fundamental to understand the molecular entities and specific pathways driving the virus replication during infection. In this paper, we review the available information on molecular determinants in disease pathobiology modules. ...
Ref: Vaccine development and therapeutic design for 2019‐nCoV/SARS‐CoV‐2: Challenges and chances [J Cell Physiol, 2020-06-18]Our approach optimizes the presentation likelihood of a diverse set of vaccine peptides conditioned on a target human-population HLA haplotype distribution and expected epitope drift.
... present a combinatorial machine learning method to evaluate and optimize peptide vaccine formulations for SARS-CoV-2. Our approach optimizes the presentation likelihood of a diverse set of vaccine peptides conditioned on a target human-population HLA haplotype distribution and expected epitope drift. Our proposed SARS-CoV-2 MHC class I vaccine formulations provide 93.21% predicted population coverage with at ...
Ref: Computationally Optimized SARS-CoV-2 MHC Class I and II Vaccine Formulations Predicted to Target Human Haplotype Distributions [Cell Syst, 2020]identified surface S glycoprotein of CoVs to be the most ideal target for vaccine development
... identified surface S glycoprotein of CoVs to be the most ideal target for vaccine development (Du et al., 2009; Schindewolf and Menachery, 2019) . During host cell receptor interaction with the S glycoprotein of the CoV, S protein undergoes cleavage directed by host cell proteases ...
Ref: Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2 [Infect Genet Evol, 2020-08-01]Vaccine technology has rapidly advanced during the last decade, facilitating development of next-generation influenza vaccines that can target a broader range of influenza viruses.
... Current influenza vaccines offer suboptimal protection and depend on annual reformulation and yearly administration. Vaccine technology has rapidly advanced during the last decade, facilitating development of next-generation influenza vaccines that can target a broader range of influenza viruses. The development and licensure of a universal influenza vaccine could provide a game changing option for ...
Ref: Prospects and challenges in the development of universal influenza vaccines [Vaccines, 2020]Carbohydrate antigens represent an important class of immunological targets for vaccine development and immunotherapy against microbial infections.
... proteomic diversities of viral pathogens, establishing versatile anti-viral vaccines or therapeutic agents is highly challenging. Carbohydrate antigens represent an important class of immunological targets for vaccine development and immunotherapy against microbial infections. In this mini review, some concepts and strategies for exploring the potential of immunogenic sugar ...
Ref: Coronaviruses' sugar shields as vaccine candidates. [Current trends in immunology, 2020]We identified 64 point mutations and 4 deletions 175 across the genomes of 44 clinical isolates,
... identify peptide epitopes that would be broadly applicable 174 in vaccine development efforts against SARS-CoV-2. We identified 64 point mutations and 4 deletions 175 across the genomes of 44 clinical isolates, with all deletions and the majority of mutations (n=45) 176 occurring in the ORF1ab polyprotein ...
Ref: Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome [bioRxiv, 2020-05-14]The severe morbidity and mortality associated with SARS-CoV-2 necessitate the development of effective vaccines to prevent epidemics.
... SARS-CoV-2, the causal agent of COVID-19, has become a major public health issue. The severe morbidity and mortality associated with SARS-CoV-2 necessitate the development of effective vaccines to prevent epidemics. There is an unprecedented need to produce and distribute enough safe and effective vaccines to individuals globally. ...
Ref: Challenges in the development of a vaccine against COVID-19 [Engineering (Beijing), 2020-09-14]The engineered vaccine sequence is adjuvanted with ß-3 defensin and comprised of B-cell epitopes, HTL epitopes and CTL epitopes.
... biology and advanced immunoinformatic strategies to devise a multi-epitope subunit vaccine against ongoing COVID-19 infection. The engineered vaccine sequence is adjuvanted with ß-3 defensin and comprised of B-cell epitopes, HTL epitopes and CTL epitopes. This is very likely that the vaccine will be able to elicit the strong immune ...
Ref: High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19 [Eur J Pharm Sci, 2020]focus on how to improve the efficacy of vaccines through adjuvant formulations.
... advances and potential strategies for vaccine development based on the spike (S) protein of SARS-CoV and MERS-CoV, and focus on how to improve the efficacy of vaccines through adjuvant formulations. Overall, these strategies may provide useful guidance for vaccine development of SARS-CoV-2. ...
Ref: Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight [Acta Pharm Sin B, 2020-05-30]Peptide microarrays can display large numbers of putative target proteins translated into overlapping linear (and cyclic) peptides.
... one hand, and antigenic targets for vaccine development on the other, are of utmost importance. Peptide microarrays can display large numbers of putative target proteins translated into overlapping linear (and cyclic) peptides. Using these highly diverse libraries, covering tens of thousands of peptides, allow for the in-depth ...
Ref: Rapid response to pandemic threats: immunogenic epitope detection of pandemic pathogens for diagnostics and vaccine development using peptide microarrays. [Journal of proteome research, 2020-09-05]Exploratory stage deals with basic research in the laboratory regarding the conceptual idea and development of an antigen against the disease against which vaccine needs to be produced.
... Exploratory stage deals with basic research in the laboratory regarding the conceptual idea and development of an antigen against the disease against which vaccine needs to be produced. It usually takes 2-4 y time. ...
Ref: Vaccine Against Covid-19 Disease – Present Status of Development [Indian J Pediatr, 2020-09-03]Vaccine developers have experimented with many different ways to present the S protein or, in some cases, the RBD domain to the immune system.
... vaccines against SARS-CoV-2. The table is incomplete but lists the most advanced and prominent candidates. Vaccine developers have experimented with many different ways to present the S protein or, in some cases, the RBD domain to the immune system. Some simply use the adjuvanted S protein as the vaccine, but many more use live ...
Ref: Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 [J Pediatric Infect Dis Soc, 2020-08-03]SARS-CoV-2 contains four structural proteins, including the nucleocapsid, membrane, envelope and S proteins [1] .
... coronavirus disease 2019 (COVID-19). However, no licensed preventative vaccines are available for COVID-19 until now. SARS-CoV-2 contains four structural proteins, including the nucleocapsid, membrane, envelope and S proteins [1] . Among them, S protein is the most important therapeutic target as it plays pivotal roles ...
Ref: A promising vaccine candidate against COVID-19 [Mol Biomed, 2020-09-30]Our findings provide a screened set of epitopes that can be introduced as potential targets for developing peptide vaccines against the SARS-CoV-2 virus.
... SARS-CoV2 proteins, we presented a set of inferred B-cell and T-cell epitopes from the spike (S) and nucleocapsid (N) proteins with high antigenicity and without allergenic property or toxic effects. Our findings provide a screened set of epitopes that can be introduced as potential targets for developing peptide vaccines against the SARS-CoV-2 virus. ...
Ref: Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review [Int Immunopharmacol, 2020]salient features of the immune response elicited by natural infection or vaccination are still uncertain.
... trajectory of the Covid-19 pandemic hinges on the dynamics of adaptive immunity against SARS-CoV2; however, salient features of the immune response elicited by natural infection or vaccination are still uncertain. We use simple epidemiological models to explore estimates for the magnitude and timing of future ...
Ref: Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. [Science, 2020-09-21]the full-length S protein and its S1 subunit (which contains receptor binding domain) have been frequently used as the vaccine antigens
... plays a crucial role in mediating virus entry. In the SARS and MERS vaccine development, the full-length S protein and its S1 subunit (which contains receptor binding domain) have been frequently used as the vaccine antigens due to their ability to induce neutralizing antibodies that prevent host cell entry and infection. ...
Ref: COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning [Front Immunol, 2020-07-03]In the case of SARS-CoV, it has been shown that only antibodies directed to S protein can neutralize the virus and prevent infection 75 .
... host cell membrane, into which the other three proteins (S, M and E) are inserted. In the case of SARS-CoV, it has been shown that only antibodies directed to S protein can neutralize the virus and prevent infection 75 . As a result, all SARS-CoV-2 vaccines in development include at least a portion of the ...
Ref: Immunological considerations for COVID-19 vaccine strategies [Nat Rev Immunol, 2020-09-04]induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates.
... we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against SARS-CoV-2 ...
Ref: Development of an inactivated vaccine candidate for SARS-CoV-2 [Science, 2020-05-06]a large number of candidate vaccines against SARS-CoV-2 are currently in the pipeline and undergoing phase I, II, and III clinical studies.
... system and by facilitating differential diagnoses with other viral/bacterial respiratory disease. On the other hand, a large number of candidate vaccines against SARS-CoV-2 are currently in the pipeline and undergoing phase I, II, and III clinical studies. As SARS-CoV-2 vaccines are expected to be marketed through accelerated regulatory pathways, vaccinovigilance as well ...
Ref: Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations [Expert Rev Vaccines, 2020]First, vaccines for infection by viruses that target and replicate in cells with FcRs,
... antigen specific. However, vaccines have several features in common that can induce VADE in vivo. First, vaccines for infection by viruses that target and replicate in cells with FcRs, including DENV and Ebola virus, are likely to induce VADE 94 , especially ADE. Up ...
Ref: Learning from the past: development of safe and effective COVID-19 vaccines [Nat Rev Microbiol, 2020-10-16]Genomic alterations were predominantly located and mapped onto the reported vaccine candidates of structural genes, which are the main targets for vaccine candidates.
... genomic structure of SARS-CoV-2 when compared to the isolates from early stages of the pandemic. Genomic alterations were predominantly located and mapped onto the reported vaccine candidates of structural genes, which are the main targets for vaccine candidates. S protein showed 34, N protein 25, E protein 2, and M protein 3 amino ...
Ref: Evolutionary Analysis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reveals Genomic Divergence with Implications for Universal Vaccine Efficacy. [Vaccines, 2020-10-08]inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al.
... immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is ...
Ref: [Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)]. [Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 2020-04-01]It has a beneficial off-target/nonspecific positive effect on the immune system which may help in an early recovery of COVID-19 patients,
... the COVID-19 impact, thus could play an important role against SARS-CoV-2 (Curtis et al.) . It has a beneficial off-target/nonspecific positive effect on the immune system which may help in an early recovery of COVID-19 patients, as found previously against several respiratory infections [79, 80] . In controlled trials, the BCG ...
Ref: Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future [Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 2020-07-27]Platform technology use systems with the same basic components as a backbone and insert new protein or genetic sequences to adapt for use against different pathogens.
... vaccine programs. 2 Rapid response platforms for vaccine development supported by CEPI are being utilized. Platform technology use systems with the same basic components as a backbone and insert new protein or genetic sequences to adapt for use against different pathogens. 3 The vaccine candidates include a DNA vaccine (administered with electroporation); a molecular-clamp vaccine (synthesis ...
Ref: Planning for COVID-19 Vaccines Safety surveillance [Vaccine, 2020-07-10]a multivalent subunit vaccine targeting S2 subunit of the SARS-CoV2 S glycoprotein has been designed using open source, immunoinformatics tools.
... and accelerate the process of vaccine development in these unprecedented times. In the present study, a multivalent subunit vaccine targeting S2 subunit of the SARS-CoV2 S glycoprotein has been designed using open source, immunoinformatics tools. Designed construct comprises of epitopes capable of inducing T cell, B cell (Linear and discontinuous) ...
Ref: Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach [J Biomol Struct Dyn, 2020]We review the antibody response that is triggered by SARS-CoV-2 infection of humans, and how it may inform vaccine research.
... that relate to the rapid "Warp Speed" development of vaccines to counter the COVID-19 pandemic. We review the antibody response that is triggered by SARS-CoV-2 infection of humans, and how it may inform vaccine research. The isolation and properties of neutralizing monoclonal antibodies from COVID-19 patients provide additional information on ...
Ref: SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds [J. virol, 2020]We also consider the many challenges of developing and deploying a new vaccine on a global scale,
... against SARS-CoV-2 - the virus that causes COVID-19 - currently undergoing early phase human trials. We also consider the many challenges of developing and deploying a new vaccine on a global scale, and recommend caution with respect to our expectations of the timeline that may be ahead. ...
Ref: Vaccines for COVID-19: The current state of play [Paediatr Respir Rev, 2020](i) parallel and adaptive development phases, (ii) innovative regulatory processes, and (iii) large production capacity.
This rapid and urgent need for the development of COVID-19 vaccines involves new development concepts: (i) parallel and adaptive development phases, (ii) innovative regulatory processes, and (iii) large production capacity.
Ref: Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development [Immunol Res, 2020-10-01]cross-binding and cross-neutralization studies using pseudoviruses, convalescent serum and polyclonal and monoclonal antibodies.
... . It is also being advanced as a potential heterologous vaccine against SARS-CoV-2 based on cross-binding and cross-neutralization studies using pseudoviruses, convalescent serum and polyclonal and monoclonal antibodies. Whether or not a heterologous vaccine might enhance the risk of ADE is unclear. For ...
Ref: COVID-19 vaccine design: the Janus face of immune enhancement [Nat Rev Immunol, 2020-04-28]It highlights antiviral strategies involving small molecules and biologics targeting complex molecular interactions involved in coronavirus infection and replication.
... overview of published scientific information with an emphasis on patents in the CAS content collection. It highlights antiviral strategies involving small molecules and biologics targeting complex molecular interactions involved in coronavirus infection and replication. The drug-repurposing effort documented herein focuses primarily on agents known to be effective against other ...
Ref: Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases [ACS Cent. Sci., 2020]Nanotechnology benefits modern vaccine design since nanomaterials are ideal for antigen delivery, as adjuvants, and as mimics of viral structures.
... development of inactivated or attenuated viral vaccines along with subunit vaccines for prophylaxis and treatment. Nanotechnology benefits modern vaccine design since nanomaterials are ideal for antigen delivery, as adjuvants, and as mimics of viral structures. In fact, the first vaccine candidate launched into clinical trials is an mRNA vaccine delivered ...
Ref: COVID-19 vaccine development and a potential nanomaterial path forward. [Nature nanotechnology, 2020-07-15]SARS-coronavirus spike proteins to produce humoral and immune response (IgG, IgA, γ-interferon, interleukin-2) in mice.
... SARS-coronavirus spike proteins to produce humoral and immune response (IgG, IgA, γ-interferon, interleukin-2) in mice. The nano-polymer polyethylenimine was used as a vaccine carrier [77] ( (Table 3 , entry 17). The major limitation of the nano-based vaccine is cellular toxicity of nano-material and need ...
Ref: Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges [Diabetes Metab Syndr, 2020-07-21]Live attenuated vaccines (LAV) are viruses that are rendered replication-incompetent through repeated passage in cell culture,
... Live attenuated vaccines (LAV) are viruses that are rendered replication-incompetent through repeated passage in cell culture, and inactivated vaccines utilise whole pathogen which has typically been killed by exposure to chemicals (e.g. formaldehyde) or heat inactivation (33) . LAV are immunogenic and reproduce the breadth of ...
Ref: The early landscape of COVID‐19 vaccine development in the UK and rest of the world [Immunology, 2020-05-27]One of the epitopes used for vaccine production is of the spike protein on the surface of virus.
... approved till now for CoV infection, trials of vaccine against SARS CoV-2 are in progress. One of the epitopes used for vaccine production is of the spike protein on the surface of virus. The work focuses on designing of multi-epitope vaccine construct for treatment of seven human CoV ...
Ref: In silico designing of multi-epitope vaccine construct against human coronavirus infections [J Biomol Struct Dyn, 2020]